Showing results (1-10 of 81) with videos related to
Sort By:
Pageof 9
Antiviral Chemistry & Chemotherapy|June 2, 2009
Novel compounds for the treatment of HIV type-1 infectionHans-Jürgen StellbrinkCore Evidence|August 10, 2010
Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infectionHans-Jürgen StellbrinkDrug Design, Development and Therapy|November 19, 2009
Raltegravir in the management of HIV-infected patientsHans-Jürgen StellbrinkEuropean Journal of Medical Research|October 16, 2007
Antiviral drugs in the treatment of AIDS: what is in the pipeline ?Hans-Jürgen StellbrinkCurrent Opinion in HIV and AIDS|May 11, 2018
Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxisHans-Jürgen Stellbrink, Christian HoffmannInfectious Diseases and Therapy|January 9, 2015
Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic ReviewCorinne Isnard Bagnis, Hans-Jürgen StellbrinkAIDS Reviews|April 25, 2014
Morbidity in older HIV-infected patients: impact of long-term antiretroviral useGiovanni Guaraldi, Manyu Prakash, Christiane Moecklinghoff, et al.Journal of the International AIDS Society|November 14, 2014
Ongoing epidemic of lymphogranuloma venereum in HIV-positive men who have sex with men: how symptoms should guide treatmentGerrit Mohrmann, Christian Noah, Michael Sabranski, et al.Deutsche Medizinische Wochenschrift (1946)|April 1, 2015
[Postexposure prophylaxis in daily clinical practice]Marc Fabian Küpper, Hans-Jürgen Stellbrink, Winfried V Kern, et al.AIDS (London, England)|September 10, 2003
Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetrationChristian Eggers, Kurt Hertogs, Hans-Jörg Stürenburg, et al.Pageof 9